Docusign Envelope ID: B27BF97B-FB32-8321-818F-4F89500DC2BC

Lundquist Institute for Biomedical Innovation
at Harbor-UCLA Medical Center

Institutional Biosafety Committee
Meeting Minutes
09/08/2026
Zoom Virtual Conference

MEMBERS PRESENT	MEMBERS ABSENT
Jonathan Abdala, B.S. David Applebaum, M.S. Begoña Diaz, Ph.D. (Chair) Rami Doueiri, Ph.D. Catalina Guerra, D.V.M. Jennifer Johnston, Ph.D. Adrienne E. Zweifel, Ph.D.	Helen Chun, Ph.D. Scott Filler, M.D.
STAFF PRESENT	**STAFF ABSENT**
Elizabeth Burrola CIP Rosa Harmon, MS, RVT, CPIA	Rosemary Madnick, MBA Annie Hilo

1. **CALL TO ORDER**
   The meeting was called to order by Begoña Diaz, Ph.D. at 3:02PM.

2. **MEETING MINUTES**
   The minutes of the 07/14/2026 meeting were presented.

   A motion was made and seconded to APPROVE the minutes with minor revision.

   Vote: For - 6, Opposed - 0, Absent – 2, Abstained - 1, Recused – 0

3. **BUA REVIEW**

   A. **Initial Reviews**
   IBC #: IBC 2026-U-SPRINT CIRM
   PI: Denise Al Alam, Ph.D.
   iRIS Ref #: 064752

   Summary: The goal of the SPRINT Core is to provide researchers and trainees with access to specialized stem cell technologies that can be used to better understand human development and disease.

   Genes of Interest: cytokines, immune response, immune signal regulators; metabolic, cytoskeletal, cytoplasmic, membrane, organelles genes, cell signal; GFP derivatives (YFP, BFP, m-Cherry); and tumor suppressor genes, transcription factors cell signaling

   Vectors: CytoTune™ 2.0 KOS (contains KLF4, OCT3/4, SOX2, cMYC); AAV; Lentivirus

   Pathogens: None

   Risk Assessment: Risk Group 1 and Risk Group 2.

Docusign Envelope ID: B27BF97B-FB32-8321-818F-4F89500DC2BC

Containment: BSL-2

Training: Training has been verified by the Research Compliance Office Staff and EHS.

NIH Guidelines: III-D; III-E; III-F

Conflicts: NA

Motion: A motion was made and seconded to REQUIRE MODIFICATIONS TO SECURE APPROVAL of the BUA.

Modifications Required to BUA:

1. Under section 9.3 (Viral Vectors):
   a. For the CytoTune 2.0 Sendai reprogramming vector discussion, the PI is to mention that this is a nonintegrating virus, but could theoretically cause transient expression of the pluripotency factors that increase cell-proliferation - a step towards tumor promotion.
   b. For the lentivirus discussion, the PI is to explicitly state (1) the generation(s) of lentiviral vector used in this work, and (2) whether the lab is purchasing packaged viral particles, or packaging infectious lentiviral particles in the lab. If the latter, the PI is to discuss the gene configurations on each plasmid and acknowledge that although extremely unlikely and rare, recombination could occur between the different plasmids used to make the virus.

2. Section 11.5 (Immune Modulation): Entry 1, the PI is to correct the typo: cytokines is spelled wrong (citokines).

3. In section 17.1 (Description of Experimental Procedures), a number of statements appear to be vague (although of note. section 17.4 and 17.6 is well written). Specifically:
   a. Specify that anEPA-registered disinfectant from EPA List S that is intended to be used when work with human materials is performed. Provide the name of the disinfectant if it has been chosen.
   b. Specify the appropriate concentration and contact time for disinfectant of liquid waste contaminated with viral vectors.
   c. It is stated, "Equipment that is not compatible with bleach will be disinfected using a manufacturer-compatible disinfectant with the appropriate efficacy claim." List the institutional approved disinfectant(s) in use if one has been chosen
   For the transfection procedures, explicitly state whether the viral vector will be pipetted onto the cells. If not, describe how this is done.

4. Under Section 17.4 (Risks - Hazardous Materials:
   a. Additional information must be provided for training minors as well as individuals not affiliated with TLI to perform these procedures.
   b. The PI is to develop an SOP to ensure all staff complete required training and reviews the BUA prior to assisting in the lab.
   c. In Section 17.4, the PI is to add the following: *The SPRINT Core lab will develop an SOP to ensure that each individual/staff member/trainee completes required training, reviews the current BUA and possesses knowledge of PPE requirements prior to assisting in the lab. Such clearances will be formally documented for*

Docusign Envelope ID: B27BF97B-FB32-8321-818F-4F89500DC2BC

each individual and maintained by the director of the SPRINT Core lab.

4. In Section 17.5 (Inactivation of biological agents)-the PI is to revisit mixed waste. It is unclear whether this needs to be checked.

5. The PI is to confirm that the cells obtained from humans will be obtained under an IRB approved protocol and with the participant's informed consent.

6. The PI is to update the BUA to require all material/service requests to submit a client request form and to provide a copy of the client request form for review by the TLI Biosafety Officer.

Vote: For - 7, Opposed - 0, Absent - 0, Abstained – 0, Recused – 0

IBC #: IBC 2026-23342-01
PI: Qiongyu Hao, M.D., Ph.D.
iRIS Ref #: 064751

Summary: This study aims to evaluate the anti-tumor efficacy of a miR-206-directed multi-drug resistance (MRS) reversal strategy, in combination with Metformin, in a diabetes-associated triple-negative breast cancer (TNBC) mouse model.

Genes of Interest: MCT4 (Monocarboxylate Transporter 4 / SLC16A3)

Vectors: None

Pathogens: None

Risk Assessment: Risk Group 1.

Containment: BSL-1

Training: Training has been verified by the Research Compliance Office Staff and EHS.

NIH Guidelines: III-F-1

Conflicts: NA

Motion: A motion was made and seconded to REQUIRE MODIFICATIONS TO SECURE APPROVAL of the BUA.

Modifications Required to BUA:

1. Section 13.0 (Research with Eukaryotic Hosts):
   a. If the murine cell lines used in this work are not the host of the miR-06 and are not genetically modified, the response to this question should be "No."
   b. Clarify if tissues harvested from the mice are used at TLI or approved under the PI's CDU BUA and used only at CDU. If the latter, remove any description of this activity from this BUA.

Docusign Envelope ID: B27BF97B-FB32-8321-818F-4F89500DC2BC

2. Section 16.5 (Terminal inactivation of biological agents): The PI is to confirm that solid waste is autoclaved on site. If it is not autoclaved on site, then describe what is done.

3. Section 16.6 (Emergency procedures): 10% bleach needs to be used here to clean BSC surfaces, but it is advisable to thoroughly clean with 70% EtOH after using bleach on a BSC surface to prevent corrosion. Select, "We will deviate from the emergency procedures as follows" to add this information.

Vote: For - 7, Opposed - 0, Absent - 0, Abstained – 0, Recused – 0

B. **Continuations**
IBC #: IBC 2023-22964-01
PI: Erick Gamelin, M.D., Ph.D.
iRIS Ref #: 064666

Summary: A novel platform for delivering therapy to cancer cells hacking the main natural way of cancer cell communication itself, nanovesicles called “exosomes” is under development. These plant-derived exosomes (isolated from ginger, lemon, and their fused formulations) naturally bind to and internalize into human cancer cells without requiring artificial chemical modifications or engineered surface ligands, leveraging their intrinsic tissue tropism and biocompatibility. The proposed work will provide proof-of-concept for this platform that utilizes natural plant exosomes to carry therapeutic cargo to specific cancer cells for therapeutic effect.

Genes of Interest: GFP, Luciferase

Vectors: None

Pathogens: None

Risk Assessment: Risk Group 2.

Containment: BSL-2

Training: Training has been verified by the Research Compliance Office Staff and EHS.

NIH Guidelines: III-D, III-F-1

Conflicts: NA

Motion: A motion was made and seconded to REQUIRE MODIFICATIONS TO SECURE APPROVAL of the BUA. Should it be determined that the plants from which the exosomes are produced are transgenic, the BUA will not be approved and must return to the IBC for review after this information has been added.

Modifications Required to BUA:

1. Renewal form, section 1.1, lab locations, add MRL 3rd floor.

2. Under Section 5.0 (Project Overview), explicitly state whether the plants from which the exosomes are produced are transgenic. If so, describe the nature of the genetic modification. Also, explicitly state the nature of the genome editing performed by the CRISPR/Cas-9

Docusign Envelope ID: B27BF97B-FB32-8321-818F-4F89500DC2BC

components delivered to the cell (insertion, deletion, substitution, etc) and where these plants will be grown.

3. Under Section 10.0 (DNA Plasmids), it is stated that no plasmids will be used, but in Section 5.1 (Project Summary), it is stated that cy5.5 labeled DNA and mRNA-GFP will be used. Then in section 11.6 (Non-hazardous nucleic acids), only mRNA will be used. Is the mRNA expressed from a plasmid? The PI is to reconcile this discrepancy.

. Section 11.6 (Non-hazardous nucleic acids), CRISPR-Cas9 is mentioned multiple times in this BUA, but isn't represented here. The PI is to reconcile this discrepancy.

4. Section 16.1 (Experimental Procedures):
   a. Provide the volumes of formalin/formaldehyde to be used such that the IBC may determine whether this procedure should be performed in a fume hood rather than in a biosafety cabinet.Section 16.2 (Biological Safety Cabinets), the PI is to correct the certification date; the cabinet was certified on 7/14/2026.

Vote: For - 7, Opposed - 0, Absent - 0, Abstained – 0, Recused – 0

4. OTHER BUSINESS

Draft NIH Policy for Research Involving Biohazards: Dr. Zweifel explained to the IBC members that the NIH Guidelines are being rewritten and asked the members to review the proposed changes and provide comments by 10/19/2026. Activities that are currently exempt may no longer be exempt if the proposed changes are implemented. The table of changes provided by the NIH Office of Science Policy highlights the most significant proposed revisions. Dr. Zweifel will prepare draft comments, to be submitted to NIH/OSP, for review by the IBC.

With no further business, the meeting adjourned at 3:59 PM.

Respectfully submitted,

Signed by:
Begona Diaz
C3FDC28E30654CD...

Begoña Díaz, Ph.D.
On behalf of the Chair,
Institutional Biosafety Committee

cc: Research Committee Agenda